

A SINGLE-BLIND, RANDOMIZED HOME-USE STUDY, IN 50 HEALTHY FEMALES (ALL WITH SELF-ASSESSED OR DIAGNOSED MENOPAUSE OR PERIMENOPAUSE), TO EVALUATE THE EFFICACY OF AN ACTIVE SUPPLEMENT IN TREATING HOT FLASHES AND NIGHT SWEATS WHEN COMPARED TO A PLACEBO, MEASURED BY SELF-PERCEPTION QUESTIONNAIRES (SPQ)

Prepared for:

Nutreance
401 Riversville Rd.
Greenwich
CT, 06831
USA

Prepared by:

Princeton Consumer Research Corp.
Baypoint Commerce Center
9600 Koger Blvd N., Suite 120,
St Petersburg
Florida, 33702

Draft Report Version 1: 21st November 2023
Draft Report Version 2: 28th November 2023
Final Report v1: 8th December 2023
Final Report v2: 12th December 2023
Final Report v3: 8th January 2024

A SINGLE-BLIND, RANDOMIZED HOME-USE STUDY, IN 50 HEALTHY FEMALES (ALL WITH SELF-ASSESSED OR DIAGNOSED MENOPAUSE OR PERIMENOPAUSE), TO EVALUATE THE EFFICACY OF AN ACTIVE SUPPLEMENT IN TREATING HOT FLASHES AND NIGHT SWEATS WHEN COMPARED TO A PLACEBO, MEASURED BY SELF-PERCEPTION QUESTIONNAIRES (SPQ)

Princeton Consumer Research Report No: NUTUSE10F

I declare that the following report constitutes a true and faithful account of the procedures adopted and the results obtained in the performance of this study. The aspects of the study conducted by PCR Corp were performed, where relevant, in accordance with the principles of Good Clinical Research Practice.

Barrie Drewitt
(Principal Investigator)

B. Drewitt

12 / 01 / 2024

Date.....

Khari Edwards
(Project Manager)

K. Edwards

11 / 01 / 2024

Date.....

QUALITY ASSURANCE STATEMENT:

This report has been audited and is considered to be an accurate description of the methods used and an accurate presentation of the data obtained during the conduct of the study.

Anne M. Campbell, BS
(Quality Assurance Auditor)

Anne M. Campbell

11 / 01 / 2024

Date.....

TABLE OF CONTENTS

| | |
|--|-----------|
| 1. SUMMARY | 4 |
| 2. KEY STUDY PERSONNEL AND RESPONSIBILITIES | 6 |
| 3. OBJECTIVE | 7 |
| 4. STUDY DESIGN | 7 |
| 5. SELECTION OF SUBJECTS..... | 7 |
| 6. METHOD..... | 8 |
| 7. STUDY ETHICS..... | 10 |
| 8. QUALITY ASSURANCE..... | 10 |
| 9. STUDY DATA..... | 10 |
| 10. STATISTICAL ANALYSIS RESULTS | 12 |
| 11. CONCLUSIONS | 15 |

APPENDICES

APPENDIX 1: FINAL STUDY PROTOCOL

APPENDIX 2: DEMOGRAPHICS

APPENDIX 3: SELF-PERCEPTION QUESTIONNAIRES (SPQS)

APPENDIX 4: RECORD RETENTION AND ADVERTISING STATEMENT

1. **SUMMARY**

| | |
|---------------------|---|
| Title: | A Single-Blind, Randomized Home-Use Study, in 50 Healthy Females (All with Self-Assessed or Diagnosed Menopause or Perimenopause), To Evaluate the Efficacy of An Active Supplement in Treating Hot Flashes and Night Sweats When Compared to A Placebo, Measured by Self-Perception Questionnaires (SPQ). |
| Study Design: | Single-blind, randomized, placebo-controlled home-use study. |
| Test Article: | 1. Nutreance Menovair Menopause Supplement 2. Placebo (empty gelatin capsules) |
| Study Duration: | 30 days |
| Number of Subjects: | Fifty-five (55) subjects were enrolled onto the study so that fifty subjects (50) subjects could be expected to complete the study. All fifty-five subjects completed the study. |
| Type of Subjects: | Healthy female volunteers, aged 40 and over with self-assessed symptoms of Menopause or Perimenopause (experiencing hot flashes, mood swings, night sweats). |
| Method: | Subjects attended the testing facility (Baseline) where Informed Consent and eligibility were verified. Once accepted, subjects were randomized to treatment (active or placebo dietary supplement, instructed on how to take the supplement. Subjects were issued the product per the randomization, to use for 30 days. Subjects were provided with a daily diary to record daily usage and any adverse reactions. Subjects returned to the testing facility after 30 days of test article use to complete the final study questionnaire. The diaries were reviewed for compliance and the test products were collected. |
| Study Dates: | Study Start Date: 27 th September 2023 Study End Date: 26 th October 2023 |
| Location: | Princeton Consumer Research Corp. Baypoint Commerce Center 9600 Koger Blvd N., Suite 120 St Petersburg, Florida 33702 |

Conclusion:

Subjects completed a Self-Perception Questionnaires (SPQ) after 30 days of the assigned test product use. Subjects were asked how strongly they agreed or disagreed to each of the SPQ statements using a 5-Point Likert Scale. The frequency of responses was summarized for each question.

Within-treatment analyses was performed using top box analysis for all questions for both the Active Test Product Treatment group and the Placebo Test Product Treatment group. The statements that had statistically significant positive responses for the Active Test Group are presented alongside the responses for each statement for the Placebo Test Group shown in the summary table below.

As shown below the Active Test Group had statistically significant positive Top Box results (Agree and Strongly Agree) to the questions listed below while the Placebo Test Group had no statistically significant positive responses to the same questions.

| Questions | Active | | Placebo | |
|--|--------|--------|---------|------|
| | % | p | % | p |
| 1. Did you notice a reduction in the intensity of hot flashes? | 69.70% | 0.04* | 31.82% | 0.13 |
| 2. Did you notice a reduction in the frequency of night sweats? | 72.73% | 0.01* | 31.82% | 0.13 |
| 5. Did you notice a reduction in the intensity of night sweats? | 69.70% | 0.04* | 36.36% | 0.29 |
| 6. Did you notice a reduction in the frequency of night sweats? | 75.76% | <0.01* | 31.82% | 0.13 |
| 16. Did you experience fewer sleep interruptions throughout the night? | 72.73% | 0.01* | 31.82% | 0.13 |
| 18. Would you recommend the product? | 72.73% | 0.01* | 31.82% | 0.13 |
| 19. Were you satisfied with the product? | 75.76% | <0.01* | 36.36% | 0.29 |

2. KEY STUDY PERSONNEL AND RESPONSIBILITIES

| Key personnel | General responsibilities |
|--|--|
| <p>Principal Investigator (PI) Barrie Drewitt PCR Corp Baypoint Commerce Center 9600 Koger Blvd N., Suite 120 St. Petersburg Florida, 33702</p> <p>Tel: +1 (727) 576-7300</p> | <p>The Principal Investigator (PI) was responsible for ensuring sufficient resources were available to conduct the study and was responsible for the study design, review of the study protocol and report and ensuring that they concurred with the study design and findings reported.</p> |
| <p>Project Manager (PM) Khari Edwards PCR Corp 8 Richmond Road Dukes Park Chelmsford Essex CM2 6UA United Kingdom</p> <p>Tel: 01245 934050</p> | <p>The Project Manager (PM) was involved with the study design, compiling the results, and writing the clinical report.</p> |
| <p>Project Supervisor (PS) Ashley Ogurek PCR Corp Baypoint Commerce Center 9600 Koger Blvd N., Suite 120 St. Petersburg Florida, 33702</p> <p>Tel: +1 (727) 576-7300</p> | <p>The Project Supervisor (PS) was responsible for the conduct of the study on a daily basis.</p> |
| <p>Project Co-ordinator (PC) Dan Watters Nutreance 401 Riversville Rd. Greenwich CT. 06831 USA</p> <p>Email: dwatters29@gmail.com</p> | <p>The PC was the primary point of contact on behalf of the Sponsor of this project and represented the Sponsor of this study.</p> |

3. OBJECTIVE

The objective of this study was to evaluate the performance of 1 Test Article (Dietary Supplement) by peri and post-menopausal women who experience menopausal symptoms. The supplement was taken at home daily. Efficacy was measured by self-perception questionnaire (SPQ) over a 30-day period. The supplement is designed to help relieve symptoms associated with menopause such as hot flashes, mood swings and night sweats.

Please note that it is the responsibility of the sponsor to determine the testing and study designs required for submission to entities such as the Home Shopping Network, QVC, etc.

4. STUDY DESIGN

Single-blind, randomized, placebo-controlled home-use study assessed by self-perception questionnaires.

5. SELECTION OF SUBJECTS

5.1 SCREENING

Subjects were screened over the telephone to allow for a sufficient number of subjects to be enrolled and issued the products to use for 30 days, so that approximately 50 subjects would be expected to complete the study. Subjects satisfied the following inclusion and exclusion criteria and were prepared to accept the prohibitions and restrictions.

The suitability of potential subjects was confirmed before their acceptance by telephone interview.

5.2 INCLUSION CRITERIA

1. Healthy female volunteers aged 40 and over of any ethnicity or skin type who are peri-or post-menopausal.
2. Subject has self-assessed symptoms of Menopause or Perimenopause (e.g., is currently experiencing hot flashes, mood swings, and/or night sweats).
3. Subject is not pregnant, trying for pregnancy or breastfeeding.
4. Subjects is taking birth control medication allowed as long as the prescription has not been changed in the last 6 months prior to the start of the study.
5. Individuals with no known medical conditions that, in the investigator's opinion, may interfere with study participation.
6. Willingness to cooperate and participate by following the study requirements.
7. Individuals must sign informed consent and confidentiality agreement.

5.3 EXCLUSION CRITERIA

1. Subject is pregnant, nursing, or planning to become pregnant.
2. Individuals that are being treated for cancer, or breast cancer. Also subjects that have any hormone-sensitive conditions such as, endometriosis, or uterine fibroids or a condition that might be made worse by exposure to estrogen.

3. Individuals currently taking certain medications which in the opinion of the Investigator, may interfere with the study. This would include but not be limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids) immunosuppressive drugs or antihistamine medications (steroid nose drops and/or eye drops are permitted), and insulin, anti-hypertensive drugs, antibiotics or OTC or prescription medications for Menopause or Menopausal Symptoms. Additionally subjects currently taking blood thinning medications.
4. Individuals with uncontrolled metabolic diseases such as diabetes (Type I and II), hypertension, hyperthyroidism or hypothyroidism, severe chronic asthma, immunological disorders such as HIV positive, AIDS and systemic lupus erythematosus or mastectomy for cancer involving removal of lymph nodes.
5. Known sensitivity/allergy to the test article, similar materials or their constituents.
6. Current participation in a similar dietary supplement study or with exclusionary requirements that would interfere with this study.

5.4 PROHIBITIONS AND RESTRICTIONS

1. Subject agrees to use the designated test article taking two (2) capsules daily during the 30-day period and to use the test article per the usage instructions provided.
2. Subject agrees not start a prescription medication course at any point during the course of the study unless approved by the Principal Investigator.
3. Subject becomes pregnant.
4. Subjects must attend both visits and complete the SPQ.
5. Subject must fill out the usage diary daily and return products at the end of the study.

6. METHOD

6.1 TEST ARTICLES

Test Articles were supplied by the Sponsor in identical commercial packaging for blinding purposes. The subjects were assigned the test products according to the randomization scheme shown below:

Subjects were assigned a test article according to the following randomization:

| | | | | | | | | | | | | | | | |
|---------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Subject # | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| Test Article | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Subject # | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| Test Article | 2 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Subject # | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 |
| Test Article | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 |
| Subject # | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | | | | | |
| Test Article | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | | | | | |

The Sponsor provided the ingredient listing the test articles and certified that the products supplied to PCR Corp for the clinical trial had been manufactured/formulated with ingredients that are safe and suitable for the product's stated purpose.

Test articles were supplied to the subjects at baseline along with directions for usage. Subjects were instructed to take the capsules twice daily at home over a 30-day period according to the following usage instructions:

Usage

For daily use: Take two (2) capsules with water every morning before having a meal.

DO NOT CONSUME ALCOHOL UNTIL YOU ARE FAMILIAR WITH THE TEST ARTICLE EFFECTS. AVOID EXCESSIVE CONSUMPTION OF ALCOHOL. KEEP OUT OF THE REACH OF CHILDREN. DO NOT EXCEED THE RECOMMENDED DOSE.

6.2 STUDY PROCEDURES AND EVALUATIONS

Visit 1 - Study Day 1 (Baseline)

Subjects attended the study facility where informed consent were collected, and eligibility was verified. Once accepted, subjects were issued the test article according to the randomization, along with instructions and a diary to record product usage.

The number of test article capsules were recorded by study staff before product was issued. Approximately thirty (30) subjects were assigned the active test article and approximately twenty (20) subjects were issued the placebo test article 2. Subjects were provided with enough test article to use for the entire 30 days.

Subjects were given a return time for their next visit and were asked to return with their daily diary and test article.

Visit 2 - Study Day 30 (± 1 Day)

Subjects returned to the testing facility after 30 days of product use for their final visit. Subjects brought their remaining test article and usage diary for review. Products were counted and compliance with the usage instructions was assessed, and diaries were also verified for compliance. Subjects were asked if they had experienced any adverse effects related to test article usage or changes to their health. Subjects completed a Self-perception Questionnaire (SPQ).

When completed subjects received compensation and their participation was considered complete.

7. STUDY ETHICS

Declaration of Helsinki and ICH Good Clinical Practices

The study conformed to the requirements of the 1964 Declaration of Helsinki and its subsequent amendments (World Medical Association; 2013). The study was conducted in accordance with applicable International Council for Harmonization. 2016. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) in as much as they apply to consumer product testing.

Subject Consent

Subjects were informed of the nature, purpose and known risk of the study both orally and in writing and gave their written informed consent before participating in the study (Appendix 1). Subjects were advised that they were free to withdraw from the study at any time without being obliged to give a reason. They were compensated for their time and inconvenience.

Indemnity Provision

The Sponsor was responsible, without regard to legal liability, and indemnified PCR Corp., or any of their respective officers or employees in the event of claims for compensation from subjects suffering injury arising out of the administration or use of the test articles, or of any procedure that was required under the protocol as a result of a subject participation in this study, except and insofar as such claims arise as a result of any negligent act or omission on the part of PCR Corp. employees or any persons undertaking or involved in the study by arrangement with PCR Corp.

8. QUALITY ASSURANCE

An audit of the final report was completed, for accuracy and completeness of presentation. Additionally, the study may have been subject to the following Quality Assurance procedures:

- Review of protocol and protocol amendments for completeness, clarity and adequacy.
- Inspection and/or audit of critical phases of study conduct for compliance with protocol and Princeton Clinical Research procedures.

The Princeton Clinical Research Corp. Quality Assurance Manager will inform Princeton Clinical Research Corp. management of any findings that may affect the integrity of the study.

9. STUDY DATA

9.1 LOCATION AND DATES OF THE STUDY

The study was performed at PCR Corp. located in St. Petersburg, Florida. The study started on 27th September 2023 and completed on 26th October 2023.

9.2 SUBJECTS

Fifty-five (55) subjects were screened and enrolled onto the study, and all fifty-five (55) subjects completed the study. Thirty-three (33) subjects were assigned use of the active supplement, and twenty-two (22) subjects were assigned use of the placebo.

A summary of subject demographics is in the table below. A complete listing of subject demographics can be found in Appendix 2.

| All Subjects | |
|-------------------------|--------------|
| Age | |
| Count | 55 |
| Mean | 57.87 |
| Std | 8.64 |
| Median | 60 |
| Range | 41 - 76 |
| Gender | |
| Female | 55 (100.0 %) |
| Race | |
| White | 27 (49.09 %) |
| Black | 27 (49.09 %) |
| Asian | 1 (1.82 %) |
| Ethnicity | |
| Non-Hispanic/Latino | 53 (96.36 %) |
| Hispanic | 2 (3.64 %) |
| Menopausal State | |
| Post | 47 (85.45 %) |
| Peri | 8 (14.55 %) |
| Test Article | |
| Supplement | 33 (60.0 %) |
| Placebo | 22 (40.0 %) |

| Active Supplement | |
|--------------------------|--------------|
| Age | |
| Count | 33 |
| Mean | 59.55 |
| Std | 8.73 |
| Median | 61 |
| Range | 41 - 76 |
| Gender | |
| Female | 33 (100.0 %) |
| Race | |
| White | 18 (54.55 %) |
| Black | 15 (45.45 %) |
| Ethnicity | |
| Non-Hispanic/Latino | 32 (96.97 %) |
| Hispanic | 1 (3.03 %) |
| Menopausal State | |
| Post | 29 (87.88 %) |
| Peri | 4 (12.12 %) |

| Placebo | |
|-------------------------|--------------|
| Age | |
| Count | 22 |
| Mean | 55.36 |
| Std | 8.06 |
| Median | 56.5 |
| Range | 43 - 68 |
| Gender | |
| Female | 22 (100.0 %) |
| Race | |
| Black | 12 (54.55 %) |
| White | 9 (40.91 %) |
| Asian | 1 (4.55 %) |
| Ethnicity | |
| Non-Hispanic/Latino | 21 (95.45 %) |
| Hispanic | 1 (4.55 %) |
| Menopausal State | |
| Post | 18 (81.82 %) |
| Peri | 4 (18.18 %) |

9.3 PROTOCOL DEVIATIONS

The protocol was followed except for one minor deviation. Subject 41 failed to return one test article container at the final visit. In the opinion of the Investigator, this deviation did not affect the integrity of the study.

9.4 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS

No adverse reactions were documented during the course of this study.

10. STATISTICAL ANALYSIS RESULTS

Data tables of individual results are included in Appendix 3.

1) Demographics:

A. Descriptive statistics (age, gender, race, ethnicity, menopausal state)

Self-Perception Questionnaire responses (5-point Likert scale) at 30 days of test article usage. The percentage of responses to each SPQ question was calculated and the percentage of the top 2 positive responses (Strongly Agree and Agree) were reported.

The frequency of responses was summarized for each question. Within-treatment analyses was performed using top box analysis.


All statistical tests of hypothesis employed a level of significance of 0.05 and no adjustments were made for the number of tests performed.

10.1 SELF-PERCEPTION QUESTIONNAIRES – SUPPLEMENT DAY 30

| Questions | Total | Not Top Box | | Top Box | | p-value |
|--|-------|-------------|--------|---------|--------|---------|
| | | N | % | N | % | |
| 1. Did you notice a reduction in the intensity of hot flashes? | 33 | 10 | 30.30% | 23 | 69.70% | 0.04* |
| 2. Did you notice a reduction in the frequency of hot flashes? | 33 | 9 | 27.27% | 24 | 72.73% | 0.01* |
| 3. Do you feel less vulnerable to hot flashes? | 33 | 12 | 36.36% | 21 | 63.64% | 0.16 |
| 4. Did you notice feeling less sensitive to temperature changes? | 33 | 15 | 45.45% | 18 | 54.55% | 0.73 |
| 5. Did you notice a reduction in the intensity of night sweats? | 33 | 10 | 30.30% | 23 | 69.70% | 0.04* |
| 6. Did you notice a reduction in the frequency of night sweats? | 33 | 8 | 24.24% | 25 | 75.76% | <0.01* |
| 7. Are you less worried about night sweats interrupting your sleep? | 33 | 13 | 39.39% | 20 | 60.61% | 0.30 |
| 8. Did you notice less frequent mood swings? | 33 | 13 | 39.39% | 20 | 60.61% | 0.30 |
| 9. Did you notice your mood was more stable? | 33 | 12 | 36.36% | 21 | 63.64% | 0.16 |
| 10. Did you notice feeling less irritable? | 33 | 14 | 42.42% | 19 | 57.58% | 0.49 |
| 11. Did you notice an improvement in your overall mood? | 33 | 11 | 33.33% | 22 | 66.67% | 0.08 |
| 12. Did you notice any weight loss or your clothes fitting better? | 33 | 27 | 81.82% | 6 | 18.18% | <0.01* |
| 13. Did you notice an improvement in your energy level? | 33 | 15 | 45.45% | 18 | 54.55% | 0.73 |
| 14. Did you notice less fatigue? | 33 | 12 | 36.36% | 21 | 63.64% | 0.16 |
| 15. Did you notice an improvement in sleep quality? | 33 | 11 | 33.33% | 22 | 66.67% | 0.08 |
| 16. Did you experience fewer sleep interruptions throughout the night? | 33 | 9 | 27.27% | 24 | 72.73% | 0.01* |
| 17. Did you notice an improvement in hair volume? | 33 | 24 | 72.73% | 9 | 27.27% | 0.01* |
| 18. Would you recommend the product? | 33 | 9 | 27.27% | 24 | 72.73% | 0.01* |
| 19. Were you satisfied with the product? | 33 | 8 | 24.24% | 25 | 75.76% | <0.01* |

Significant if p-value < 0.05; Please note that in some cases Not Top Box was statistically significant.

SPQ - SUPPLEMENT




10.2 SELF-PERCEPTION QUESTIONNAIRES – PLACEBO DAY 30

| Questions | Total | Not Top Box | | Top Box | | p-value |
|--|-------|-------------|--------|---------|--------|---------|
| | | N | % | N | % | |
| 1. Did you notice a reduction in the intensity of hot flashes? | 22 | 15 | 68.18% | 7 | 31.82% | 0.13 |
| 2. Did you notice a reduction in the frequency of hot flashes? | 22 | 15 | 68.18% | 7 | 31.82% | 0.13 |
| 3. Do you feel less vulnerable to hot flashes? | 22 | 15 | 68.18% | 7 | 31.82% | 0.13 |
| 4. Did you notice feeling less sensitive to temperature changes? | 22 | 15 | 68.18% | 7 | 31.82% | 0.13 |
| 5. Did you notice a reduction in the intensity of night sweats? | 22 | 14 | 63.64% | 8 | 36.36% | 0.29 |
| 6. Did you notice a reduction in the frequency of night sweats? | 22 | 15 | 68.18% | 7 | 31.82% | 0.13 |
| 7. Are you less worried about night sweats interrupting your sleep? | 22 | 14 | 63.64% | 8 | 36.36% | 0.29 |
| 8. Did you notice less frequent mood swings? | 22 | 16 | 72.73% | 6 | 27.27% | 0.05* |
| 9. Did you notice your mood was more stable? | 22 | 17 | 77.27% | 5 | 22.73% | 0.02* |
| 10. Did you notice feeling less irritable? | 22 | 16 | 72.73% | 6 | 27.27% | 0.05* |
| 11. Did you notice an improvement in your overall mood? | 22 | 16 | 72.73% | 6 | 27.27% | 0.05* |
| 12. Did you notice any weight loss or your clothes fitting better? | 22 | 18 | 81.82% | 4 | 18.18% | <0.01* |
| 13. Did you notice an improvement in your energy level? | 22 | 15 | 68.18% | 7 | 31.82% | 0.13 |
| 14. Did you notice less fatigue? | 22 | 16 | 72.73% | 6 | 27.27% | 0.05* |
| 15. Did you notice an improvement in sleep quality? | 22 | 15 | 68.18% | 7 | 31.82% | 0.13 |
| 16. Did you experience fewer sleep interruptions throughout the night? | 22 | 15 | 68.18% | 7 | 31.82% | 0.13 |
| 17. Did you notice an improvement in hair volume? | 22 | 18 | 81.82% | 4 | 18.18% | <0.01* |
| 18. Would you recommend the product? | 22 | 15 | 68.18% | 7 | 31.82% | 0.13 |
| 19. Were you satisfied with the product? | 22 | 14 | 63.64% | 8 | 36.36% | 0.29 |

Significant if p-value < 0.05; Please note, all statistically significant responses were for Not Top Box.

SPQ - PLACEBO



11. CONCLUSIONS

Subjects completed a Self-Perception Questionnaires (SPQ) after 30 days of the assigned test product use. Subjects were asked how strongly they agreed or disagreed to each of the SPQ statements using a 5-Point Likert Scale. The frequency of responses was summarized for each question.

Within-treatment analyses was performed using top box analysis for all questions for both the Active Test Product Treatment group and the Placebo Test Product Treatment group. The statements that had statistically significant positive responses for the Active Test Group are presented alongside the responses for each statement for the Placebo Test Group shown in the summary table below.

As shown below the Active Test Group had statistically significant positive Top Box results (Agree and Strongly Agree) to the questions listed below while the Placebo Test Group had no statistically significant positive responses to the same questions.

| Questions | Active | | Placebo | |
|--|--------|--------|---------|------|
| | % | p | % | p |
| 1. Did you notice a reduction in the intensity of hot flashes? | 69.70% | 0.04* | 31.82% | 0.13 |
| 2. Did you notice a reduction in the frequency of night sweats? | 72.73% | 0.01* | 31.82% | 0.13 |
| 5. Did you notice a reduction in the intensity of night sweats? | 69.70% | 0.04* | 36.36% | 0.29 |
| 6. Did you notice a reduction in the frequency of night sweats? | 75.76% | <0.01* | 31.82% | 0.13 |
| 16. Did you experience fewer sleep interruptions throughout the night? | 72.73% | 0.01* | 31.82% | 0.13 |
| 18. Would you recommend the product? | 72.73% | 0.01* | 31.82% | 0.13 |
| 19. Were you satisfied with the product? | 75.76% | <0.01* | 36.36% | 0.29 |

No subjects reported any adverse events or reactions while participating on the study.

PCR CORP

2.1 DEMOGRAPHICS

| Subject/ Rando # | Age | Gender | Race | Ethnicity | Date of Last Menstrual Cycle | Menopausal State | Test Article |
|---------------------|-----|--------|-------|---------------------|---------------------------------|------------------|--------------|
| 01 | 60 | Female | White | Hispanic | May-14 | Post | Placebo |
| 02 | 55 | Female | White | Non-Hispanic/Latino | Mar-18 | Post | Supplement |
| 03 | 58 | Female | Black | Non-Hispanic/Latino | Mar-12 | Post | Placebo |
| 04 | 49 | Female | Black | Non-Hispanic/Latino | Mar-23 | Peri | Supplement |
| 05 | 43 | Female | Black | Non-Hispanic/Latino | Unk-10 | Post | Placebo |
| 06 | 70 | Female | White | Non-Hispanic/Latino | Dec-09 | Post | Supplement |
| 07 | 69 | Female | White | Non-Hispanic/Latino | Unk-13 | Post | Supplement |
| 08 | 64 | Female | Black | Non-Hispanic/Latino | Sep-03 | Post | Supplement |
| 09 | 66 | Female | Black | Non-Hispanic/Latino | Mar-08 | Post | Placebo |
| 10 | 47 | Female | Asian | Non-Hispanic/Latino | Mar-21 | Post | Placebo |
| 11 | 68 | Female | White | Non-Hispanic/Latino | Unk-02 | Post | Placebo |
| 12 | 43 | Female | White | Non-Hispanic/Latino | Sep-23 | Peri | Placebo |
| 13 | 51 | Female | White | Non-Hispanic/Latino | Jul-15 | Post | Supplement |
| 14 | 41 | Female | Black | Non-Hispanic/Latino | Sep-23 | Peri | Supplement |
| 15 | 69 | Female | Black | Non-Hispanic/Latino | Unk-13 | Post | Supplement |
| 16 | 45 | Female | White | Non-Hispanic/Latino | Jan-15 | Post | Placebo |
| 17 | 53 | Female | White | Non-Hispanic/Latino | Dec-13 | Post | Supplement |
| 18 | 60 | Female | Black | Non-Hispanic/Latino | Nov-98 | Post | Placebo |
| 19 | 57 | Female | White | Non-Hispanic/Latino | Sep-19 | Post | Supplement |
| 20 | 60 | Female | Black | Non-Hispanic/Latino | Jun-07 | Post | Placebo |
| 21 | 52 | Female | White | Non-Hispanic/Latino | Unk-17 | Post | Supplement |
| 22 | 76 | Female | White | Non-Hispanic/Latino | Jul-77 | Post | Supplement |
| 23 | 54 | Female | Black | Non-Hispanic/Latino | Jun-23 | Peri | Supplement |
| 24 | 65 | Female | Black | Non-Hispanic/Latino | Dec-07 | Post | Supplement |
| 25 | 51 | Female | Black | Non-Hispanic/Latino | Unk-18 | Post | Supplement |
| 26 | 68 | Female | Black | Non-Hispanic/Latino | Aug-18 | Post | Supplement |
| 27 | 64 | Female | White | Non-Hispanic/Latino | Dec-14 | Post | Supplement |
| 28 | 57 | Female | Black | Non-Hispanic/Latino | Unk-06 | Post | Supplement |
| 29 | 60 | Female | White | Non-Hispanic/Latino | Dec-18 | Post | Placebo |
| 30 | 65 | Female | Black | Non-Hispanic/Latino | Mar-19 | Post | Supplement |
| 31 | 68 | Female | White | Non-Hispanic/Latino | May-96 | Post | Supplement |
| 32 | 49 | Female | Black | Non-Hispanic/Latino | Sep-23 | Peri | Placebo |
| 33 | 55 | Female | Black | Non-Hispanic/Latino | Jun-22 | Post | Placebo |
| 34 | 63 | Female | Black | Non-Hispanic/Latino | Aug-13 | Post | Placebo |
| 35 | 55 | Female | Black | Non-Hispanic/Latino | Unk-19 | Post | Placebo |
| 36 | 53 | Female | White | Non-Hispanic/Latino | Sep-17 | Post | Supplement |
| 37 | 50 | Female | White | Non-Hispanic/Latino | Unk-95 | Post | Supplement |
| 38 | 48 | Female | White | Non-Hispanic/Latino | Unk-15 | Post | Supplement |
| 39 | 64 | Female | White | Non-Hispanic/Latino | Apr-08 | Post | Placebo |
| 40 | 63 | Female | Black | Non-Hispanic/Latino | Unk-08 | Post | Supplement |
| 41 | 46 | Female | White | Non-Hispanic/Latino | Sep-23 | Peri | Placebo |
| 42 | 66 | Female | White | Hispanic | Unk-19 | Post | Supplement |
| 43 | 72 | Female | White | Non-Hispanic/Latino | Feb-99 | Post | Supplement |
| 44 | 66 | Female | White | Non-Hispanic/Latino | Feb-06 | Post | Supplement |
| 45 | 60 | Female | Black | Non-Hispanic/Latino | Feb-10 | Post | Supplement |
| 46 | 44 | Female | Black | Non-Hispanic/Latino | Aug-23 | Peri | Placebo |
| 47 | 65 | Female | White | Non-Hispanic/Latino | Feb-12 | Post | Placebo |
| 48 | 55 | Female | Black | Non-Hispanic/Latino | Mar-21 | Post | Placebo |
| 49 | 61 | Female | Black | Non-Hispanic/Latino | Dec-00 | Post | Supplement |
| 50 | 63 | Female | Black | Non-Hispanic/Latino | Dec-10 | Post | Supplement |
| 51 | 52 | Female | Black | Non-Hispanic/Latino | Aug-18 | Post | Placebo |
| 52 | 42 | Female | White | Non-Hispanic/Latino | Aug-23 | Peri | Supplement |
| 53 | 65 | Female | White | Non-Hispanic/Latino | Dec-16 | Post | Supplement |
| 54 | 60 | Female | White | Non-Hispanic/Latino | Jun-13 | Post | Placebo |
| 55 | 58 | Female | Black | Non-Hispanic/Latino | Mar-06 | Post | Supplement |

Supplement Count = 33 | Placebo Count = 22

3.1 SELF-PERCEPTION QUESTIONNAIRE – Active Supplement

| Subject Number | 1. Did you notice a reduction in the intensity of hot flashes? | 2. Did you notice a reduction in the frequency of hot flashes? | 3. Do you feel less vulnerable to hot flashes? | 4. Did you notice feeling less sensitive to temperature changes? | 5. Did you notice a reduction in the intensity of night sweats? | 6. Did you notice a reduction in the frequency of night sweats? | 7. Are you less worried about night sweats interrupting your sleep? | 8. Did you notice less frequent mood swings? | 9. Did you notice your mood was more stable? | 10. Did you notice feeling less irritable? | 11. Did you notice an improvement in your overall mood? | 12. Did you notice any weight loss or your clothes fitting better? | 13. Did you notice an improvement in your energy level? | 14. Did you notice less fatigue? | 15. Did you notice an improvement in sleep quality? | 16. Did you experience fewer sleep interruptions throughout the night? | 17. Did you notice an improvement in hair volume? | 18. Would you recommend the product? | 19. Were you satisfied with the product? |
|----------------|--|--|--|--|---|---|---|--|--|--|---|--|---|----------------------------------|---|--|---|--------------------------------------|--|
| 2 | Agree | Strongly Agree | Agree | Agree | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Agree | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree |
| 4 | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Agree | Neither Agree Nor Disagree | Agree | Disagree | Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree |
| 6 | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree |
| 7 | Agree | Agree | Strongly Agree | Agree | Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Disagree | Neither Agree Nor Disagree | Agree | Agree | Strongly Agree | Neither Agree Nor Disagree | Strongly Agree | Strongly Agree |
| 8 | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Strongly Disagree | Disagree | Agree | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 13 | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Agree |
| 14 | Agree | Agree | Agree | Agree | Agree | Strongly Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree |
| 15 | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Strongly Agree | Strongly Agree |
| 17 | Agree | Agree | Agree | Neither Agree Nor Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Agree | Agree |
| 19 | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree |
| 21 | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 22 | Agree | Agree | Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Strongly Agree | Strongly Agree |
| 23 | Agree | Strongly Agree | Agree | Agree | Strongly Agree | Strongly Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Strongly Agree |
| 24 | Strongly Agree | Agree | Agree | Agree | Strongly Agree | Agree | Strongly Agree | Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Strongly Agree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Strongly Agree | Strongly Agree |
| 25 | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Agree |
| 26 | Agree | Agree | Strongly Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Strongly Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Agree | Agree | Strongly Agree |

| Subject Number | 1. Did you notice a reduction in the intensity of hot flashes? | 2. Did you notice a reduction in the frequency of hot flashes? | 3. Do you feel less vulnerable to hot flashes? | 4. Did you notice feeling less sensitive to temperature changes? | 5. Did you notice a reduction in the intensity of night sweats? | 6. Did you notice a reduction in the frequency of night sweats? | 7. Are you less worried about night sweats interrupting your sleep? | 8. Did you notice less frequent mood swings? | 9. Did you notice your mood was more stable? | 10. Did you notice feeling less irritable? | 11. Did you notice an improvement in your overall mood? | 12. Did you notice any weight loss or your clothes fitting better? | 13. Did you notice an improvement in your energy level? | 14. Did you notice less fatigue? | 15. Did you notice an improvement in sleep quality? | 16. Did you experience fewer sleep interruptions throughout the night? | 17. Did you notice an improvement in hair volume? | 18. Would you recommend the product? | 19. Were you satisfied with the product? |
|----------------|--|--|--|--|---|---|---|--|--|--|---|--|---|----------------------------------|---|--|---|--------------------------------------|--|
| 27 | Disagree | Agree | Neither Agree Nor Disagree | Disagree | Disagree | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Agree | Agree | Agree | Agree | Disagree | Agree | Agree |
| 28 | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Agree | Strongly Agree | Agree | Strongly Agree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Strongly Agree | Strongly Agree |
| 30 | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree |
| 31 | Disagree | Disagree | Disagree | Disagree | Strongly Disagree | Strongly Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Disagree | Strongly Disagree | Neither Agree Nor Disagree | Disagree |
| 36 | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree |
| 37 | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Strongly Disagree | Strongly Disagree | Neither Agree Nor Disagree | Strongly Disagree | Strongly Disagree |
| 38 | Agree | Agree | Strongly Agree | Neither Agree Nor Disagree | Agree | Strongly Agree | Strongly Agree | Agree | Agree | Agree | Agree | Disagree | Agree | Agree | Agree | Agree | Disagree | Strongly Agree | Agree |
| 40 | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Neither Agree Nor Disagree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Neither Agree Nor Disagree | Strongly Agree | Strongly Agree |
| 42 | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Agree | Strongly Agree | Agree | Agree |
| 43 | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree |
| 44 | Neither Agree Nor Disagree | Disagree | Agree | Disagree | Neither Agree Nor Disagree | Agree | Disagree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree |
| 45 | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree |
| 49 | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree |
| 50 | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 52 | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Agree |
| 53 | Agree | Strongly Agree | Strongly Agree | Agree | Strongly Disagree | Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Agree | Agree | Strongly Agree | Strongly Agree |
| 55 | Strongly Agree | Disagree | Agree | Agree | Agree | Disagree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Strongly Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Agree | Neither Agree Nor Disagree | Disagree | Disagree |

3.2 SELF-PERCEPTION QUESTIONNAIRE – Placebo

| Subject Number | 1. Did you notice a reduction in the intensity of hot flashes? | 2. Did you notice a reduction in the frequency of hot flashes? | 3. Do you feel less vulnerable to hot flashes? | 4. Did you notice feeling less sensitive to temperature changes? | 5. Did you notice a reduction in the intensity of night sweats? | 6. Did you notice a reduction in the frequency of night sweats? | 7. Are you less worried about night sweats interrupting your sleep? | 8. Did you notice less frequent mood swings? | 9. Did you notice your mood was more stable? | 10. Did you notice feeling less irritable? | 11. Did you notice an improvement in your overall mood? | 12. Did you notice any weight loss or your clothes fitting better? | 13. Did you notice an improvement in your energy level? | 14. Did you notice less fatigue? | 15. Did you notice an improvement in sleep quality? | 16. Did you experience fewer sleep interruptions throughout the night? | 17. Did you notice an improvement in hair volume? | 18. Would you recommend the product? | 19. Were you satisfied with the product? | |
|----------------|--|--|--|--|---|---|---|--|--|--|---|--|---|----------------------------------|---|--|---|--------------------------------------|--|----------------------------|
| 1 | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree |
| 3 | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree |
| 5 | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 9 | Neither Agree Nor Disagree | Strongly Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 10 | Agree | Agree | Neither Agree Nor Disagree | Agree | Strongly Agree | Agree | Agree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Strongly Agree | Strongly Agree | Neither Agree Nor Disagree | Agree | Strongly Agree | Strongly Agree |
| 11 | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Strongly Agree | Strongly Agree | Strongly Agree |
| 12 | Disagree | Neither Agree Nor Disagree | Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 16 | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 18 | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Agree |
| 20 | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 29 | Strongly Disagree | Strongly Disagree | Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree |
| 32 | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree |
| 33 | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 34 | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Agree | Strongly Agree | Strongly Agree | Strongly Agree | Strongly Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree |
| 35 | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree |
| 39 | Strongly Agree | Agree | Strongly Agree | Strongly Agree | Agree | Strongly Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree |
| 41 | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree |
| 46 | Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Disagree | Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Strongly Disagree | Strongly Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Disagree |
| 47 | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Disagree | Neither Agree Nor Disagree | Disagree | Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree |
| 48 | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree | Agree |
| 51 | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Strongly Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree | Strongly Disagree |
| 54 | Agree | Agree | Agree | Neither Agree Nor Disagree | Agree | Agree | Agree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Neither Agree Nor Disagree | Agree | Neither Agree Nor Disagree | Agree | Agree | Disagree | Agree | Agree | Agree |

RECORD RETENTION STATEMENT

All study source documents, and a copy of the signed final report will remain on file with PCR Corp. for a period of at least 3 years, at the end of which time the Sponsor will be contacted for transfer of the files to their own archive or permission obtained to destroy these records. A permanent record of the study will be retained in a readily retrievable form.

ADVERTISING STATEMENT

PCR Corp. submits this report with the understanding that the Sponsor may use the study report for its own purposes. PCR Corp. agrees, not to use the name of the Sponsor or any derivation thereof, in any publication without the prior written consent of the Sponsor.

USE OF PCR CORP., STAFF NAMES, SYMBOLS, WATERMARKS AND LOGOS:

This report may be used by the Sponsor for their own purpose. However, the Sponsor shall not use or authorize any others to use the company name, staff names, symbols, watermarks and logos of PCR Corp. in any advertisements, or any marketing material or allow use of any statement or representation in relation to the study, that is suggestive of an implied endorsement by PCR Corp. of the product or service without a written approval from PCR Corp.